Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
Provided By GlobeNewswire
Last update: Dec 4, 2024
Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio
Submissions to Health Canada planned for 2025
Read more at globenewswire.com
